Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 117

1.

Galantamine treatment in Alzheimer's disease: response and long-term outcome in a routine clinical setting.

Wallin AK, Wattmo C, Minthon L.

Neuropsychiatr Dis Treat. 2011;7:565-76. doi: 10.2147/NDT.S24196. Epub 2011 Sep 30.

2.

Galantamine for Alzheimer's disease.

Olin J, Schneider L.

Cochrane Database Syst Rev. 2002;(3):CD001747. Review. Update in: Cochrane Database Syst Rev. 2004;(4):CD001747.

PMID:
12137632
3.

Galantamine for Alzheimer's disease.

Olin J, Schneider L.

Cochrane Database Syst Rev. 2001;(4):CD001747. Review. Update in: Cochrane Database Syst Rev. 2002;(3):CD001747.

PMID:
11687119
4.

Galantamine provides sustained benefits in patients with 'advanced moderate' Alzheimer's disease for at least 12 months.

Blesa R, Davidson M, Kurz A, Reichman W, van Baelen B, Schwalen S.

Dement Geriatr Cogn Disord. 2003;15(2):79-87.

PMID:
12566596
5.

Progression of mild Alzheimer's disease: knowledge and prediction models required for future treatment strategies.

Wattmo C, Wallin AK, Minthon L.

Alzheimers Res Ther. 2013 Oct 7;5(5):44. doi: 10.1186/alzrt210. eCollection 2013.

6.

Galantamine for Alzheimer's disease and mild cognitive impairment.

Loy C, Schneider L.

Cochrane Database Syst Rev. 2006 Jan 25;(1):CD001747. Review.

PMID:
16437436
7.

Patterns of decline and evidence of subgroups in patients with Alzheimer's disease taking galantamine for up to 48 months.

Rockwood K, Dai D, Mitnitski A.

Int J Geriatr Psychiatry. 2008 Feb;23(2):207-14.

PMID:
17621382
8.

A naturalistic study of galantamine for Alzheimer's disease.

Brodaty H, Woodward M, Boundy K, Barnes N, Allen G; NATURE Investigators.

CNS Drugs. 2006;20(11):935-43.

PMID:
17044730
9.

Mild versus moderate stages of Alzheimer's disease: three-year outcomes in a routine clinical setting of cholinesterase inhibitor therapy.

Wattmo C, Minthon L, Wallin ÅK.

Alzheimers Res Ther. 2016 Feb 17;8:7. doi: 10.1186/s13195-016-0174-1.

10.

Galantamine for Alzheimer's disease.

Loy C, Schneider L.

Cochrane Database Syst Rev. 2004 Oct 18;(4):CD001747. Review. Update in: Cochrane Database Syst Rev. 2006;(1):CD001747.

PMID:
15495017
11.

Long-term response to galantamine in relation to short-term efficacy data: pooled analysis in patients with mild to moderate Alzheimer's disease.

Kavanagh S, Howe I, Brashear HR, Wang D, van Baelen B, Todd M, Schwalen S.

Curr Alzheimer Res. 2011 Mar;8(2):175-86.

12.

Management of patients with Alzheimer's disease plus cerebrovascular disease: 12-month treatment with galantamine.

Bullock R, Erkinjuntti T, Lilienfeld S; GAL-INT-6 Study Group.

Dement Geriatr Cogn Disord. 2004;17(1-2):29-34. Epub 2003 Oct 13.

PMID:
14560062
13.

Carotid intima-media thickness as a predictor of response to cholinesterase inhibitors in Alzheimer's disease: an open-label trial.

Modrego PJ, Rios C, Pérez Trullen JM, García-Gómara MJ, Errea JM.

CNS Drugs. 2009;23(3):253-60. doi: 10.2165/00023210-200923030-00006.

PMID:
19320533
14.

An open-label, comparative study of rivastigmine, donepezil and galantamine in a real-world setting.

Aguglia E, Onor ML, Saina M, Maso E.

Curr Med Res Opin. 2004 Nov;20(11):1747-52.

PMID:
15537474
15.

Donepezil in Alzheimer's disease: what to expect after 3 years of treatment in a routine clinical setting.

Wallin AK, Andreasen N, Eriksson S, Båtsman S, Nasman B, Ekdahl A, Kilander L, Grut M, Rydén M, Wallin A, Jonsson M, Olofsson H, Londos E, Wattmo C, Eriksdotter Jonhagen M, Minthon L; Swedish Alzheimer Treatment Study Group.

Dement Geriatr Cogn Disord. 2007;23(3):150-60. Epub 2006 Dec 18.

PMID:
17312368
16.

Galantamine for Alzheimer's disease.

Olin J, Schneider L.

Cochrane Database Syst Rev. 2001;(1):CD001747. Review. Update in: Cochrane Database Syst Rev. 2001;(4):CD001747.

PMID:
11279727
17.

Response to cholinesterase inhibitors affects lifespan in Alzheimer's disease.

Wattmo C, Londos E, Minthon L.

BMC Neurol. 2014 Sep 10;14:173. doi: 10.1186/s12883-014-0173-4.

18.

Early- versus late-onset Alzheimer's disease in clinical practice: cognitive and global outcomes over 3 years.

Wattmo C, Wallin ÅK.

Alzheimers Res Ther. 2017 Aug 31;9(1):70. doi: 10.1186/s13195-017-0294-2.

19.

A prospective, double-blind, community-controlled comparison of three doses of galantamine in the treatment of mild to moderate Alzheimer's disease in a Korean population.

Suh GH, Yeon Jung H, Uk Lee C, Hoon Oh B, Nam Bae J, Jung HY, Ju YS, Kil Yeon B, Park J, Hong I, Choi S, Ho Lee J; Korean Galantamine Study Group.

Clin Ther. 2004 Oct;26(10):1608-18.

PMID:
15598477
20.

Dose and plasma concentration of galantamine in Alzheimer's disease - clinical application.

Wattmo C, Jedenius E, Blennow K, Wallin AK.

Alzheimers Res Ther. 2013 Jan 3;5(1):2. doi: 10.1186/alzrt156. eCollection 2013.

Supplemental Content

Support Center